Cancer cachexia is a debilitating multi-factorial wasting syndrome characterised by severe skeletal muscle and dysfunction (i.e., myopathy). In the oncology setting, arises from synergistic insults both cancer–host interactions chemotherapy-related toxicity. The majority of studies have surrounded interaction side cancer cachexia, often overlooking capability chemotherapy to induce cachectic my...

BACKGROUND Cancer associated cachexia affects the majority of cancer patients during the course of the disease and thought to be directly responsible for about a quarter of all cancer deaths. Current evidence suggests that a pro-inflammatory state may be associated with this syndrome although the molecular mechanisms responsible for the development of cachexia are poorly understood. The purpose...

Cachexia is a life threatening syndrome associated with several diseases, such as end-stage heart failure, end-stage renal disease, chronic obstructive pulmonary disease, chronic inflammation (i.e. rheumatoid arthritis), acquired immune deficiency syndrome, and cancer. Cachexia is found in 31–87% of cancer patients especially in advanced disease stages. It is characterized by progressive weight...

Even though most clinical data on cachexia have been reported from Western countries, cachexia may be a growing problem in Asia as well, as the population in this area of the world is considerably larger. Considering the current definitions of obesity and sarcopenia in Japan, which are different from the ones in Western countries, the lack of a distinct cachexia definition in Japan is strinking...

Cancer-related anorexia and cachexia syndrome (CACS) is a complex multifactorial condition, with loss of lean body mass, chronic inflammation, severe metabolic derangements, reduced food intake, reduced physical activity, and poor quality of life as key symptoms. Cachexia recognizes different phases or stages, moving from precachexia through overt cachexia to advanced or refractory cachexia. Th...

Introduction. Cachexia is a syndrome characterized by the loss of musculoskeletal mass, with or without adipose which cannot be reversed nutritional support. In Chile, there are no data on cachexia in cancer patients that allows for decision making better interdisciplinary management. this study, prevalence inpatient and outpatient was investigated. Methods. An observational, descriptive, cross...

Cachexia causes weight loss and increased mortality. It affects more than 5 million persons in the United States. Other causes of weight loss include anorexia, sarcopenia, and dehydration. The pathophysiology of cachexia is reviewed in this article. The major cause appears to be cytokine excess. Other potential mediators include testosterone and insulin-like growth factor I deficiency, excess m...

cer, acute nonlymphocytic leukemia, and sarcomas have a low frequency of weight loss (31–40%) (16). This suggests that cachexia-inducing tumors may have an altered genetic expression that allows them to produce factors that degrade triglyceride stores in adipose tissue and myofibrillar proteins in skeletal muscle. Certainly cachexia bears no simple correlation to tumor burden, metastasis, or an...

Muscle atrophy (cachexia) in cancer patients is a life-threatening condition for which therapeutic options are limited. Zhou et al. (2010) now identify a new target for treating cachexia, the activin type-2 receptor (ActRIIB). In several mouse models of cachexia, the authors reversed wasting of skeletal and cardiac muscle and increased life span by blocking ActRIIB with a decoy receptor.

AIMS Adiponectin is a fat-derived hormone involved in the regulation of metabolism. Adiponectin concentration is inversely related to body weight and, in animals, causes weight loss. We, therefore, measured adiponectin concentration in patients with heart failure (HF) and cachexia. METHODS AND RESULTS Serum adiponectin concentrations were measured in three groups of patients with coronary art...